Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 16, 2015
Reporting Period: Fiscal fourth quarter and fiscal year ended May 31, 2015.
This filing serves as a notification that the Company issued a press release announcing financial results for the specified period. The detailed financial data is contained in the attached press release (Exhibit 99.1) and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of the press release containing the results for the fiscal year ended May 31, 2015.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document includes a comprehensive disclaimer regarding forward-looking statements. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially.
Identified Risks and Uncertainties:
- Economic, credit, and capital market conditions affecting the general economy and medical device companies.
- Domestic and foreign health care reforms and governmental laws/regulations.
- Third-party relations, approvals, and technological advances by competitors.
- Challenges in new product development, including obtaining regulatory approvals.
- Future actions by the FDA or other regulatory agencies.
- Results of pending or future clinical trials.
- Outcome of pending litigation.
- Foreign currency exchange rate fluctuations.
- Pricing effects from group purchasing organizations and competition.
- Ability to integrate purchased businesses.
The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, earnings, and cash flow figures for the fiscal year ended May 31, 2015.
- Verify the status of pending litigation and clinical trials mentioned in the risk factors.
- Assess the impact of current health care reforms and regulatory actions by the FDA on the Company's product pipeline.
- Confirm the Company's ability to integrate any recently purchased businesses as referenced in the risk disclosures.